Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-acetic acid | IC50: 0.00026 mM | Bos taurus | |
(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-acetic acid methyl ester | 35% inhibition of ALR2 at 0.05 mM | Bos taurus | |
(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetic acid | IC50: 0.00017 mM | Bos taurus | |
(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetic acid methyl ester | 12% inhibition of ALR2 at 0.05 mM | Bos taurus | |
4-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-2-butenoic acid | 21% inhibition of ALR2 at 0.05 mM | Bos taurus | |
4-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-2-butenoic acid methyl ester | 6% inhibition of ALR2 at 0.05 mM | Bos taurus | |
4-[2,4-dioxo-5-(3-phenoxybenzylidene)thiazolidin-3-yl]-2-butenoic acid | 19% inhibition of ALR2 at 0.05 mM | Bos taurus | |
4-[2,4-dioxo-5-(3-phenoxybenzylidene)thiazolidin-3-yl]-2-butenoic acid methyl ester | 25% inhibition of ALR2 at 0.05 mM | Bos taurus | |
4-[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]-2-butenoic acid | 57% inhibition of ALR2 at 0.05 mM | Bos taurus | |
4-[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]-2-butenoic acid methyl ester | 23% inhibition of ALR2 at 0.05 mM | Bos taurus | |
4-[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]-2-butenoic acid | IC50: 0.0042 mM | Bos taurus | |
5-(3-aminobenzylidene)-2,4-thiazolidinedione | IC50: 0.0202 mM | Bos taurus | |
5-(3-hydroxybenzylidene)-2,4-thiazolidinedione | IC50: 0.0107 mM | Bos taurus | |
5-(3-nitrobenzylidene)-2,4-thiazolidinedione | 21% inhibition of ALR2 at 0.05 mM | Bos taurus | |
5-(4-aminobenzylidene)-2,4-thiazolidinedione | 44% inhibition of ALR2 at 0.05 mM | Bos taurus | |
5-(4-benzyloxybenzylidene)-2,4-thiazolidinedione | 10% inhibition of ALR2 at 0.05 mM | Bos taurus | |
5-(4-hydroxybenzylidene)-2,4-thiazolidinedione | IC50: 0.009 mM | Bos taurus | |
5-(4-nitrobenzylidene)-2,4-thiazolidinedione | 37% inhibition of ALR2 at 0.05 mM | Bos taurus | |
5-biphenyl-4-ylmethylene-2,4-thiazolidinedione | 20% inhibition of ALR2 at 0.05 mM | Bos taurus | |
5-naphthalen-1-ylmethylene-2,4-thiazolidinedione | IC50: 0.0107 mM | Bos taurus | |
epalrestat | - |
Bos taurus | |
additional information | molecular modelling, enzyme docking at the active site of the enzyme, structure-activity relationships of 5-arylidene-2,4-thiazolidinediones, an additional aromatic ring or an H-bond donor group on the 5-benzylidene ring enhance ALR2 inhibitory potency, the presence of a carboxylic anionic chain on N-3 is important, and the length of the carboxylic chain is critical, overview, no inhibition by 5b 4-[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]-2-butenoic acid methyl ester | Bos taurus | |
ponalrestat | IC50: 80 nM | Bos taurus | |
sorbinil | IC50: 0.0011 mM | Bos taurus | |
zopolrestat | - |
Bos taurus | |
[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]acetic acid | IC50: 0.00082 mM | Bos taurus | |
[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]acetic acid methyl ester | 33% inhibition of ALR2 at 0.05 mM | Bos taurus | |
[5-(3-aminobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester | IC50: 0.039 mM | Bos taurus | |
[5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid | IC50: 0.00066 mM | Bos taurus | |
[5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester | 43% inhibition of ALR2 at 0.05 mM | Bos taurus | |
[5-(3-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid | IC50: 0.00049 mM | Bos taurus | |
[5-(3-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester | 22% inhibition of ALR2 at 0.05 mM | Bos taurus | |
[5-(4-aminobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester | 25% inhibition of ALR2 at 0.05 mM | Bos taurus | |
[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid | IC50: 0.00028 mM | Bos taurus | |
[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester | 12% inhibition of ALR2 at 0.05 mM | Bos taurus | |
[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid | IC50: 0.00015 mM | Bos taurus | |
[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester | IC50: 0.0062 mM | Bos taurus | |
[5-(4-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid | IC50: 0.0012 mM | Bos taurus | |
[5-(4-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester | 8% inhibition of ALR2 at 0.05 mM | Bos taurus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Bos taurus | - |
- |
- |
Purification (Comment) | Organism |
---|---|
native enzyme from lens by anion exchange chromatography | Bos taurus |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
lens | - |
Bos taurus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
glyceraldehyde + NADPH + H+ | - |
Bos taurus | glycerol + NADP+ | - |
? |
Synonyms | Comment | Organism |
---|---|---|
aldose reductase | - |
Bos taurus |
ALR2 | - |
Bos taurus |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Bos taurus |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
6.8 | - |
assay at | Bos taurus |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
NADPH | - |
Bos taurus |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.00008 | - |
IC50: 80 nM | Bos taurus | ponalrestat | |
0.00015 | - |
IC50: 0.00015 mM | Bos taurus | [5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid | |
0.00017 | - |
IC50: 0.00017 mM | Bos taurus | (5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetic acid | |
0.00026 | - |
IC50: 0.00026 mM | Bos taurus | (5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-acetic acid | |
0.00028 | - |
IC50: 0.00028 mM | Bos taurus | [5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid | |
0.00049 | - |
IC50: 0.00049 mM | Bos taurus | [5-(3-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid | |
0.00066 | - |
IC50: 0.00066 mM | Bos taurus | [5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid | |
0.00082 | - |
IC50: 0.00082 mM | Bos taurus | [2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]acetic acid | |
0.0011 | - |
IC50: 0.0011 mM | Bos taurus | sorbinil | |
0.0012 | - |
IC50: 0.0012 mM | Bos taurus | [5-(4-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid | |
0.0042 | - |
IC50: 0.0042 mM | Bos taurus | 4-[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]-2-butenoic acid | |
0.0062 | - |
IC50: 0.0062 mM | Bos taurus | [5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester | |
0.009 | - |
IC50: 0.009 mM | Bos taurus | 5-(4-hydroxybenzylidene)-2,4-thiazolidinedione | |
0.0107 | - |
IC50: 0.0107 mM | Bos taurus | 5-naphthalen-1-ylmethylene-2,4-thiazolidinedione | |
0.0107 | - |
IC50: 0.0107 mM | Bos taurus | 5-(3-hydroxybenzylidene)-2,4-thiazolidinedione | |
0.0202 | - |
IC50: 0.0202 mM | Bos taurus | 5-(3-aminobenzylidene)-2,4-thiazolidinedione | |
0.039 | - |
IC50: 0.039 mM | Bos taurus | [5-(3-aminobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester |